Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for Nephroprotection in T2DM
NCT06430125Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nicorandil in chronic kidney disease (CKD) (2 arms), sponsored by Tanta University. Primary endpoint: prevention of progression of kidney disease as measured by KDIGO at 12 weeks. Started Feb 2023; status: recruiting.
02
Drugs
nicorandil
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06430125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430125.